This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Drugdevelopment is more of a sprint than a marathon these days, thanks to more and better ways to target underlying biology and a more nuanced interpretation of precision medicine, three biotech leaders said at the STAT Breakthrough Summit East in New York Thursday. Continue to STAT+ to read the full story…
Drugdevelopment is essentially a long, expensive bet: 90% of drugs fail during clinical trials, goes one of the life science industry’s most oft-quoted statistics. But they cautioned that the pace of future successes will depend on whether the industry can streamline and rethink drugdevelopment.
SAN DIEGO — Cancer vaccines have traveled a potholed road over the last decade. The promise has long been an affordable, personalized cancer vaccine that could train the immune system to recognize proteins from cancer cells and, subsequently, destroy the tumor.
A study billed as the last chance to develop an HIV vaccine this decade has been shut down, investigators announced Wednesday at a conference in Harare, Zimbabwe. The trial, known as PrEPVacc, was testing two different vaccine regimens on about 1,500 volunteers in East and Southern Africa. Read the rest…
Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at Mass General Cancer Center. But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta.
Today, we talk about the uptick in physicians using ctDNA to determine if resected cancers are truly gone, we see the FDA offering new guidelines for Covid-19 vaccines, and more. Sign up to get our biotech newsletter in your inbox. Read the rest…
Also, Moderna’s RSV vaccine efficacy seems lackluster compared to competitors, and the Bernie Sanders drug pricing song-and-dance did not seem to faze pharma CEOs. Sign up to get our biotech newsletter in your inbox. Give it a listen. Read the rest…
A Marburg fever outbreak in Equatorial Guinea is galvanizing efforts to test drugs and vaccines for a virus that currently has none. But every day counts, warned experts who gathered virtually on Tuesday to try to chart a course for the work.
Damian here with a rare look at a biotech in collapse, Moderna’s ambitious future in vaccines, and what looks like a massive missed opportunity. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, all. Read the rest…
We see a new startup emerge that aims to compete with Vertex Pharmaceuticals, and learn of Phase 1 results for Replicate’s srRNA rabies vaccine. Today, we discuss how Biogen’s missed the mark with Leqembi, but how it’s also not exactly a surprise. Read the rest…
BOSTON — GSK has been developingvaccines under one corporate guise or another for 140 years, ever since a rural Pennsylvania doctor started pumping smallpox shots out of a converted chicken house in 1882, but the company may be most known today for the vaccine it didn’t build.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we get into why Amy Abernethy is leaving Verily, and why the ongoing reckoning with AI doesn’t necessarily need the voice of Google to chime in.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today, we discuss how psychedelics companies are responding to the negative ad comm vote on Lykos’ therapy, results of Zepbound in MASH, and the fate of Novovax this fall.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with an update on the biotech market, a look at the future of genome editing, and the evolving definition of “insider trading.” ” Read the rest…
During the Covid-19 pandemic, vaccines were the main line of defense. Yet the need for effective antivirals remains even with strong vaccines, to protect people who are unvaccinated, immunocompromised, or otherwise unable to build an antibody response to a vaccine. Antiviral treatments were not as impactful.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Wall Street had a big reaction to H5N1 bird flu news yesterday. Was it warranted? We’ll discuss that today. Read the rest…
Support for community vaccination campaigns has dwindled. government will stop paying for Covid vaccines and treatments, which could widen gaps in access as the products move to being covered by insurance. States are reporting outbreak data less frequently, and globally, testing and surveillance programs have been curtailed.
Given the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress, the Triple Negative Breast Cancer (TNBC) DrugDevelopment Digital Summi t has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint, DDR inhibitor, ADC and other novel agents.
There’s potential that a stem cell infusion from kidney donors might help prevent organ rejection — allowing patients to perhaps wean from immunosuppressive drugs. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Lots on vaccines this morning: Moderna says its combination shot for Covid and flu works well, and might help improve uptake in the broader population. And the FDA just cleared GSK’s RSV vaccine for younger at-risk adults. Want to stay on top of the science and politics driving biotech today? Read the rest…
A new study suggests the antiviral drug obeldesivir may be effective in curing Ebola Sudan infections, for which there are currently no approved vaccines or treatments.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Big news this morning, so let’s get straight into it. Read the rest…
We also examine how Covid-19 vaccine makers are faring today, and more. Today, we discuss the implications of the Supreme Court’s forthcoming mifepristone evaluation on the FDA and the biopharma industry. Read the rest…
Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine.
Look at Covid, how many vaccines do we have?” “We should not be passive about it. We’re not passive about any other condition,” she told STAT. “Look at HIV, how many antiretrovirals do we have? ” Continue to STAT+ to read the full story…
In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development.
The vaccine maker Novavax, which has faced several years of dramatic ups and downs around the development of its Covid-19 vaccine, announced Monday that its CEO of more than 11 years, Stanley Erck, would be stepping down. Investors had not been expecting the departure, but cheered the news.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we have two FDA approvals, preview late-breakers at this weekend’s American Heart Association scientific sessions, and offer up your very favorite podcast. Read the rest…
After all, it opens the door for Medicare to negotiate the price of small-molecule drugs after nine years on the market (as opposed to 13 years for biologic drugs like vaccines, cell therapies, or gene therapies). But the law hasn’t brought a total halt to all such drugdevelopment — at least, not yet.
LONDON — Moderna may be best known for its Covid-19 vaccine, but since its start, it’s always been set on developing therapies. But the company’s vision of making cells into their own drug factories is showing signs of progress.
It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccinedevelopment. Innovative new vaccines are being created more rapidly than ever before.
Damian here with an update on the plight of the other Covid-19 vaccine company, Wall Street’s latest GLP-1 trade, and the quest for a universal antivenom. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, all.
Today, we talk about the much-awaited CRISPR-based drug Casgevy, discuss the new Gavi initiative that plans to dramatically ramp up vaccine manufacturing in Africa, and more. Sign up to get our biotech newsletter in your inbox. Have a nice weekend! Read the rest…
’s most commonly used vaccines for Covid-19. Moderna and BioNTech, massively profitable companies that have sold more than $80 billion worth of Covid-19 vaccines combined, have singled out oncology as the next big application for mRNA and invested accordingly. Continue to STAT+ to read the full story…
Good morning Pharmalittle students. This is Allison DeAngelis, filling in for Ed Silverman while he’s away from the Pharmalot campus. I debated assigning you a “What I did on my summer vacation” essay to write over the weekend. Instead, we’re going to discuss the latest healthcare news!
The state’s biotech scene exploded in the mid-2010s and early in the pandemic as exuberant investors disregarded the high failure rate in drugdevelopment and bet on buzzy technologies such as gene editing and messenger RNA vaccines. And although many companies are making layoffs, others are expanding.
Today, we talk a lot about regulatory policy — for flu vaccines and for physicians. Sign up to get our biotech newsletter in your inbox. Hope you had a restful and reflective long weekend.
Today, some amazing intel on Merck’s Ebola vaccine: Turns out, it can reduce risk of death, even after a person has been infected. Also, investors bet on another obesity drug — this time from BioAge, which is combining Zepbound with a pill that keeps muscle wasting at bay. It’s Meghana.
With demand for fast-tracking therapies, vaccines and other products increasing, companies like Azzur Group offer the ability to add capabilities quickly.
Pfizer and partner BioNTech have launched a countersuit against Moderna in a patent despite centring on their mRNA-based vaccines for COVID-19. It also waived its rights to bring the lawsuit when it pledged not to sure other COVID-19 vaccine producers during the pandemic, according to Reuters.
We also learn about a new initiative to try and prevent gonorrhea spread with a meningitis vaccine. Lots of news on the cardiovascular front this morning: We discuss Novo Nordisk’s plans in heart disease, and Verve’s gene editing therapy for familial hypercholesterolemia. Read the rest…
COVID-19 has been a trial-by-fire showing just how quickly drugs and vaccines can be developed under the right circumstances – but there is much to do to ensure this progress is not lost, said speakers at WIRED Health 2021, including the CEOs of BioNTech and BenevolentAI. . BioNTech seeks “new kind of pharma company”.
Today, we talk about how Bernie Sanders might be hitting a wall with the drug industry, see a glimmer of potential for HIV vaccines, and introduce a new Monday fundraising feature. Sign up to get our biotech newsletter in your inbox. Read the rest…
Enjoy, and see you soon… In a surprise move, Doctors Without Borders is closing down its access-to-medicines campaign, which has been credited with ensuring needed drugs and vaccines have been made available to countless patients in low-income countries around the world , STAT reports.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content